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ABSTRACT
Objective  Variants in CLEC16A have conferred 
susceptibility to autoimmune diseases in genome-
wide association studies. The present work aimed to 
investigate the locus’ involvements in juvenile idiopathic 
arthritis (JIA) and further explore the association 
with rheumatoid arthritis (RA), type 1 diabetes (T1D) 
and Addison’s disease (AD) in the Norwegian 
population.
Methods  Three single nucleotide polymorphisms (SNPs) 
were genotyped in patients with RA (n=809), JIA 
(n=509), T1D (n=1211) and AD (n=414) and in healthy 
controls (n=2149).
Results  All diseases were associated with CLEC16A, 
but with different SNPs. The intron 22 SNP, rs6498169, 
was associated with RA (p=0.006) and JIA (p=0.016) 
and the intron 19 SNPs, rs12708716/rs12917716, with 
T1D (p=1×10−5) and AD (p=2×10−4). The RA 
association was conﬁ  ned to the anti-cyclic citrullinated 
peptide antibody (anti-CCP) negative subgroup 
(p=2×10−4).
Conclusion  This is the ﬁ  rst report of a CLEC16A 
association with JIA and a split of the RA association 
according to anti-CCP status. Different causative 
variants underlie the rheumatic versus the organ speciﬁ  c 
diseases.
INTRODUCTION
Genome-wide association studies (GWAS) have 
recently identiﬁ   ed single nucleotide polymor-
phisms (SNPs) in C-type lectin domain family 16, 
member A (CLEC16A) to be associated with the 
autoimmune diseases; type 1 diabetes (T1D)1 2 
and multiple sclerosis (MS).3 To date, the function 
of CLEC16A remains unknown. A role in immu-
nity is however likely since it is almost exclusively 
expressed in immune cells, such as dendritic cells, 
B lymphocytes and natural killer cells (http://
symatlas.gnf.org/SymAtlas/). The gene is classiﬁ  ed 
as a C-type lectin based on bioinformatic analyses, 
although atypical, as it lacks crucial domains in car-
bohydrate recognition.4
We have earlier reported a positive associa-
tion between polymorphisms in CLEC16A and 
Addison’s disease (AD),5 and such evidence was 
also recently reported in rheumatoid arthritis 
(RA).6 Different polymorphisms in CLEC16A have 
been reported to be disease associated in differ-
ent autoimmune diseases, with a possible expla-
nation that studies have not analysed the same 
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SNP sets. However, there is extensive linkage 
  disequilibrium (LD) between the most strongly 
associated SNPs, and a representative subset of 
these SNPs was analysed in this study to attempt 
to ascertain if these associations could point to a 
common SNP, or if the associations in fact rely on 
different SNPs.
Our aim was to provide further support for 
CLEC16A as an autoimmune risk locus and in par-
ticular to address the potential role in susceptibility 
to juvenile idiopathic arthritis (JIA), a disease not 
previously studied in this context, as well as to fur-
ther explore its putative role in RA.
PATIENTS AND METHODS
Patients and controls
The panel of autoimmune diseases consisted of 
809 patients with RA, 509 with JIA, 1211 with 
T1D and 414 with AD (see supplementary mate-
rial). Controls were recruited from 2 independent 
cohorts: 1029 from set 1 and 1120 from set 2. 
All individuals were Norwegian Caucasians and 
informed consent was given by all participants in 
compliance with the Helsinki Declaration.
SNP selection
First, based on the dense tagging of SNPs analysed 
in our previous study on AD,5 we decided to geno-
type the strongest associated SNP, rs12917716, in 
the other disease sample sets and an enlarged AD 
sample set. Second, based on the LD pattern and 
haplotypes between the SNPs that have shown 
association with other autoimmune diseases (sup-
plementary ﬁ  gure 1A),1–3 together with the knowl-
edge that RA and T1D have shown association 
with different SNPs in CLEC16A,6 we also geno-
typed rs12708716 and rs6498169 in the RA, JIA and 
T1D samples. Rs12708716 was earlier analysed in 
332 AD samples and rs6498169 was then tagged by 
rs27838 (r2=0.97).5
Genotyping
Genotyping of rs12917716, rs12708716 and 
rs6498169 was performed using predesigned 
TaqMan SNP Genotyping Assays (Applied 
Biosystems, Foster City, California, USA), except 
rs12917716, rs12708716 and rs27838 in the previ-
ously published AD samples and control set 1,5 
which were analysed with SNPlex Genotyping 
System (Applied Biosystems).
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Serology
An ELISA kit assay (INOVA Diagnostics, San Diego, California, 
USA) was used to measure anti-cyclic citrullinated peptide anti-
body (anti-CCP) concentrations in the RA samples, with a posi-
tivity cut-off deﬁ  ned as levels >25 U/ml.
Statistical analyses
Power calculations (α=0.05) were performed using R V.2.6.1,7 
assuming an OR of 1.25 and an allele frequency of 40%; fairly 
representative for the three analysed SNPs. Estimated power 
was for RA 97%, JIA 89%, T1D 99% and AD 83%. Allele and 
genotype analyses were performed in Plink V.1.058 based on χ2 
contingency tables. Reported p values are two sided and not 
adjusted for multiple testing because of the strong correlation 
between the genotyped SNPs. Haplotype constructions and 
regression analyses to estimate haplotype risks were performed 
using Unphased V.3.1.1,9 choosing the haplotype formed by the 
protective alleles as baseline reference.
RESULTS
All four autoimmune diseases showed associations with SNPs 
in CLEC16A (table 1). RA and JIA were signiﬁ  cantly associated 
with the intron 22 SNP, rs6498169. In contrast, T1D and AD 
proved to be strongly associated with the two intron 19 SNPs, 
rs12708716 and rs12917716. There was strong LD between 
rs12708716 and rs12917716 in the Norwegian population with 
D′=0.99 and r2=0.69 (supplementary ﬁ  gure 1B). Both were also 
in partial LD with rs6498169 with D′>0.88 and r2>0.24. The 
associations in RA, T1D and AD ﬁ  tted an additive model, while 
the signiﬁ  cance in the JIA cohort was highest in a recessive 
model (p=0.003).
These ﬁ  ndings raised the question whether there appear to 
be different causal variants in RA and JIA compared with T1D 
and AD. Hence we investigated haplotypes to explore if dif-
ferent risk haplotypes emerged, or if one common haplotype 
could explain these different association patterns (supplemen-
tary table 1). When constructing haplotypes of rs12917716–
rs6498169, the rs6498169 risk allele G appeared only on 
haplotype IV, which was signiﬁ  cantly associated with RA, JIA 
and T1D. The risk for this haplotype was more or less the same 
as the single SNP analysis of rs6498196 in JIA and RA, con-
cluding that this SNP alone mark their association within the 
CLEC16A locus and that adding the T1D/AD associated SNP 
rs12917716 in a haplotype did not result in a better marker for 
the RA and JIA association.
Haplotype construction in T1D revealed that haplotypes III 
and IV with different rs6498196 allele had similar risk estimates, 
suggesting that this SNP cannot explain the T1D association, 
in contrast with what was observed in RA and JIA. AD was in 
line with T1D, suggesting that the rs12708716–rs12917716 risk 
haplotypes (III and IV) pointed to an untyped SNP, in strong LD 
with both, to be the causative variant.
The anti-CCP status has been shown to divide patients with 
RA into two groups clinically and genetically and we therefore 
considered it relevant to stratify the patients with RA based 
Table 1  Association analyses of single nucleotide polymorphisms (SNPs) in the CLEC16A gene
RA JIA T1D AD Control set 1 Control set 2 Controls total
rs12708716:
Genotype
  AA 374 (46.8%) 240 (47.3%) 607 (50.9%) NA1 434 (42.6%) 474 (43.5%) 908 (43.1%)
  AG 352 (44.0%) 213 (42.0%) 481 (40.3%) 468 (45.9%) 494 (45.3%) 962 (45.6%)
  GG 74 (9.3%) 54 (10.7%) 105 (8.8%) 117 (11.5%) 122 (11.2%) 239 (11.3%)
  Total 800 (100%) 507 (100%) 1193 (100%) 1019 (100%) 1090 (100%) 2109 (100%)
Allele
 MAF 31.3 31.7 29.0 34.4 33.9 34.1
 OR 0.88 0.89 0.79
 p  Value 0.036 0.13 1×10−5
rs12917716:
Genotype
  GG 278 (34.8%) 194 (38.6%) 459 (38.2%) 161 (39.3%) 333 (32.5%) 365 (32.7%) 698 (32.6%)
  GC 393 (49.2%) 219 (43.5%) 568 (47.3%) 206 (50.2%) 515 (50.2%) 555 (49.8%) 1070 (50,0%)
  CC 127 (15.9%) 90 (17.9%) 175 (14.6%) 43 (10.5%) 177 (17.3%) 195 (17.5%) 372 (17.4%)
  Total 798 (100%) 503 (100%) 1202 (100%) 410 (100%) 1025 (100%) 1115 (100%) 2140 (100%)
Allele
 MAF 40.5 39.7 38.2 35.4 42.4 42.4 42.4
 OR 0.93 0.89 0.84 0.75
  95% CI 0.82 to 1.04 0.78 to 1.03 0.76 to 0.93 0.64 to 0.87
 p  Value 0.20 0.12 8×10−4 2×10−4
Rs6498169:
Genotype
  AA 276 (35.7%) 184 (36.9%) 450 (37.5%) NA1 408 (39.8%) 440 (40.5%) 848 (40.2%)
  AG 380 (49.1%) 230 (46.2%) 577 (48.1%) 493 (48.1%) 517 (47.6%) 1010 (47.9%)
  GG 118 (15.2%) 84 (16.9%) 173 (14.4%) 123 (12.0%) 129 (11.9%) 252 (11.9%)
  Total 774 (100%) 498 (100%) 1200 (100%) 1024 (100%) 1086 (100%) 2110 (100%)
  95% CI 1.05 to 1.33 1.03 to 1.37 1.01 to 1.24
 p  Value 0.006 0.016 0.036
In an earlier study including 332 of the patients, rs12708716 gave an OR of 0.74 (0.61 to 0.90), p=0.003. Rs6498169 was then tagged by rs27838 which had an OR of 1.04 (0.86 to 
1.25).5
AD, Addison’s disease; JIA, juvenile idiopathic arthritis; MAF, minor allele frequency; OR, odds ratio given for the minor allele versus the major allele; RA, rheumatoid arthritis; T1D, type 
1 diabetes.
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on anti-CCP status. This revealed that the association with 
rs6498196 followed the patients who were anti-CCP negative 
as allele G was signiﬁ  cantly increased among patients who were 
anti-CCP negative (44.0%) compared to patients who were anti-
CCP positive (37.7%) or controls (35.9%), OR=1.40 (95% CI 
1.18 to 1.68), p=2×10−4 (table 2). There was no evidence of sig-
niﬁ  cantly different allele frequencies among JIA subtypes (p=0.2) 
(supplementary table 2).
DISCUSSION
CLEC16A polymorphisms were initially detected as suscep-
tibility markers for T1D and MS in GWAS;1–3 associations, 
which have thereafter shown their resemblance to other 
populations,4 6 10–13 now also with T1D in Norwegians. Our 
results conﬁ  rm the recently reported association with RA in a 
Spanish population,6 but demonstrated that this association is 
restricted to patients who were anti-CCP negative. Further, an 
association with JIA was demonstrated for the ﬁ  rst time.
Interestingly, our results indicate that different causative 
SNPs underlie the systemic autoimmune diseases, RA and 
JIA and the organ speciﬁ  c diseases, T1D and AD, included in 
this study. The rheumatic disorders RA and JIA are caused by 
inﬂ  ammation of the joints, even though their clinical features 
differ signiﬁ  cantly. However, T1D and AD are anticipated to 
share some genetic background as almost 10% of the patients 
with AD have concomitant T1D. Studies in MS are inconclusive 
regarding which SNP in CLEC16A is the most strongly associ-
ated. Rs12708716 did not initially pass the quality check in the 
GWA reporting on rs6498169 as the strongest association,3 but 
has subsequently been reported with equivalent risk estimates 
in the same sample set.14 The other initially reported T1D SNP, 
rs2903692,1 is located in the same intron as rs6498169, but in 
stronger LD with rs12708716 than rs6498169 (supplementary 
ﬁ  gure 1A). Also the risk estimates for rs2903692 were indistin-
guishable from the rs6498169 risk in the MS sample reported 
by Martínez et al.6 However, rs2903692, and not rs6498169, 
showed evidence of association in a subgroup of patients with 
Crohn’s disease.15 Rs2903692 was not genotyped in our study 
due to the strong correlation with rs12708716 and rs12917716.
The identiﬁ  cation of clinical subsets of heterogeneous dis-
eases is important for the understanding of their genetic basis. 
This has been clearly demonstrated in RA where different human 
leucocyte antigen (HLA) DRB1 associations in the context of anti-
CCP antibody status have been reported; DRB1 shared epitope 
(SE) association being restricted to patients who were anti-CCP 
positive, and the DRB1*03 haplotype associated with RA solely 
in patients who were anti-CCP negative.16 Also non-HLA asso-
ciations have been dependent on subclassiﬁ  cation of anti-CCP, 
for example, CTLA4 and peptidyl arginine deiminase type IV 
(PADI4) are associated with patients who are anti-CCP posi-
tive.17 Conversely, the CLEC16A association with RA in the pres-
ent study was restricted to the anti-CCP negative subgroup, as 
has also been reported for interferon regulatory factor 5 (IRF5).18 
It should be noted that Martínez et al did not detect any 
difference in CLEC16A association when stratifying for anti-
CCP, but their statistical power was also lower.6
Our study highly supports variants within CLEC16A to tag 
a common autoimmunity predisposing locus. Further effort is 
needed to understand the function of CLEC16A and the splicing 
variants within this LD block, and also to identify the causative 
variants, which seem to differ between the autoimmune diseases.
Acknowledgements  The Norwegian Bone Marrow Donor Registry is acknowledged 
for contributing DNA from healthy controls. The authors thank Anne-Marit Selvaag for 
collecting JIA samples and Gry Namløs Nordang for excellent administration of the RA 
sample set (Oslo University Hospital, Rikshospitalet).
Funding  This research was supported by grants from EU FP7, Grant number 201167, 
Euradrenal and the South-Eastern Regional Health Authorities.
Competing interests  J WJ Bijlsma was the handling editor for this manuscript.
Ethics approval  This study was conducted with the approval of the Regional Ethical 
Committees of Western and South Eastern Norway and the Data inspectorate of 
Norway.
Provenance and peer review  Not commissioned; externally peer reviewed.
REFERENCES
 1.  Hakonarson H, Grant SF, Bradﬁ  eld JP, et al. A genome-wide association study 
identiﬁ  es KIAA0350 as a type 1 diabetes gene. Nature 2007;448:591–4.
 2.  The Wellcome Trust Case Control Consortium. Genome-wide association study 
of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 
2007;447:661–78.
 3.  Haﬂ  er DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identiﬁ  ed 
by a genomewide study. N Engl J Med 2007;357:851–62.
 4.  Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome 
regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007;39:857–64.
 5.  Skinningsrud B, Husebye ES, Pearce SH, et al. Polymorphisms in CLEC16A and CIITA 
at 16p13 are associated with primary adrenal insufﬁ  ciency. J Clin Endocrinol Metab 
2008;93:3310–17.
 6.  Martínez A, Perdigones N, Cénit M, et al. Chromosomal region 16p13: further 
evidence of increased predisposition to immune diseases. Ann Rheum Dis 2009;In 
Press.
 7.  R Development Core Team. http://www.R-project.org (accessed 2 March 2009).
 8.  Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum Genet 
2007;81:559–75.
 9.  Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated 
subjects with missing genotype data. Hum Hered 2008;66:87–98.
10.  Awata T, Kawasaki E, Tanaka S, et al. Association of type 1 diabetes with two Loci 
on 12q13 and 16p13 and the inﬂ  uence coexisting thyroid autoimmunity in Japanese. 
J Clin Endocrinol Metab 2009;94:231–5.
11.  Rubio JP, Stankovich J, Field J, et al. Replication of KIAA0350, IL2RA, RPL5 
and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun 
2008;9:624–30.
12.  Wu X, Zhu X, Wang X, et al. Intron polymorphism in the KIAA0350 gene is 
reproducibly associated with susceptibility to type 1 diabetes (T1D) in the Han 
Chinese population. Clin Endocrinol (Oxf) 2009;71:46–9.
13.  Zoledziewska M, Costa G, Pitzalis M, et al. Variation within the CLEC16A gene 
shows consistent disease association with both multiple sclerosis and type 1 diabetes 
in Sardinia. Genes Immun 2009;10:15–17.
14.  International Multiple Sclerosis Genetics Consortium. The expanding genetic 
overlap between multiple sclerosis and type I diabetes. Genes Immun 2009;10:11–14.
15.  Márquez A, Varadé J, Robledo G, et al. Speciﬁ  c association of a CLEC16A/KIAA0350 
polymorphism with NOD2/CARD15(-) Crohn’s disease patients. Eur J Hum Genet 
2009;17:1304–8.
Table 2  Association of rs6498169 stratiﬁ  ed on anti-CCP status in patients with RA
n A G MAF
Cases vs controls G vs A Cases only G vs A
OR (95 % CI) p Value OR (95 % CI) p Value
Controls 2110 2706 1514 35.9 1.00
Anti-CCP+ 454 566 342 37.7 1.08 (0.93 to 1.25) 0.3 1.00
Anti-CCP− 283 317 249 44.0 1.40 (1.18 to 1.68) 2×10−4 1.30 (1.05 to 1.61) 0.016
Anti-CCP, anti-cyclic citrullinated peptide; MAF, minor allele frequency; RA, rheumatoid arthritis.
12_annrheumdis114934.indd   1473 12_annrheumdis114934.indd   1473 7/5/2010   3:17:30 PM 7/5/2010   3:17:30 PMConcise report
Ann Rheum Dis 2010;69:1471–1474. doi:10.1136/ard.2009.114934 1474
Sweden: association of susceptibility with PTPN22, CTLA4 and PADI4. Am J Hum 
Genet 2005;77:1044–60.
18.  Sigurdsson S, Padyukov L, Kurreeman FA, et al. Association of a haplotype in the 
promoter region of the interfseron regulatory factor 5 gene with rheumatoid arthritis. 
Arthritis Rheum 2007;56:2202–10.
16.  Irigoyen P, Lee AT, Wener MH, et al. Regulation of anti-cyclic citrullinated peptide 
antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared 
epitope alleles. Arthritis Rheum 2005;52:3813–18.
17.  Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene 
associations with rheumatoid arthritis in >4,000 samples from North America and 
12_annrheumdis114934.indd   1474 12_annrheumdis114934.indd   1474 7/5/2010   3:17:30 PM 7/5/2010   3:17:30 PM